Pascal and Francis Bibliographic Databases

Help

Search results

Your search

kw.\*:("Rituximab")

Document Type [dt]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Language

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 2545

  • Page / 102
Export

Selection :

  • and

'rituximab-induced inhibition of antiapoptotic cell survival pathways : implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions'BONAVIDA, B.Oncogene (Basingstoke). 2007, Vol 26, Num 25, pp 3629-3636, issn 0950-9232, 8 p.Article

Rituximab (Rituxan)SELEWSKI, D. T; SHAH, G. V; MODY, R. J et al.American journal of neuroradiology. 2010, Vol 31, Num 7, pp 1178-1180, issn 0195-6108, 3 p.Article

Treatment of stiff person syndrome with rituximabBAKER, M. R; DAS, M; ISAACS, J et al.Journal of neurology, neurosurgery and psychiatry. 2005, Vol 76, Num 7, pp 999-1001, issn 0022-3050, 3 p.Article

Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIgRÜEGG, Stephan J; FUHR, Peter; STECK, Andreas J et al.Neurology. 2004, Vol 63, Num 11, pp 2178-2179, issn 0028-3878, 2 p.Article

Le rituximab hors AMM en auto-immunité = Off-label use of rituximabCORNEC, D; SARAUX, A.La Lettre du rhumatologue. 2011, Num 372, pp 22-27, issn 0761-5027, 6 p.Article

Identification of compounds that enhance the anti-lymphoma activity of rituximab using flow cytometric high-content screeningGASPARETTO, Maura; GENTRY, Tracy; SMITH, Clay et al.Journal of immunological methods. 2004, Vol 292, Num 1-2, pp 59-71, issn 0022-1759, 13 p.Article

Rituximab for tumefactive inflammatory demyelination: A case reportXUEWEN FAN; MAHTA, Ali; DE JAGER, Philip L et al.Clinical neurology and neurosurgery (Dutch-Flemish ed.). 2012, Vol 114, Num 10, pp 1326-1328, issn 0303-8467, 3 p.Article

Successful treatment with rituximab of one patient with CANOMAD neuropathyDELMONT, Emilien; JEANDEL, P. Y; HUBERT, A. M et al.Journal of neurology. 2010, Vol 257, Num 4, pp 655-657, issn 0340-5354, 3 p.Article

An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromesSHAMS'ILI, Setareh; DE BEUKELAAR, Janet; GRATAMA, Jan Willem et al.Journal of neurology. 2006, Vol 253, Num 1, pp 16-20, issn 0340-5354, 5 p.Article

The Anti-CD20 Antibody Rituximab Reduces the Th17 Cell ResponseVAN DE VEERDONK, Frank L; LAUWERYS, Bernard; VAN DEN BERG, Wim B et al.Arthritis and rheumatism. 2011, Vol 63, Num 6, pp 1507-1516, issn 0004-3591, 10 p.Article

Does rituximab aggravate pre-existing hypogammaglobulinaemia?DIWAKAR, Lavanya; GORRIE, Sheryl; RICHTER, Alex et al.Journal of clinical pathology. 2010, Vol 63, Num 3, pp 275-277, issn 0021-9746, 3 p.Article

Innovative Uses of Rituximab in DermatologyCARR, David R; HEFFERNAN, Michael P.Dermatologic clinics. 2010, Vol 28, Num 3, issn 0733-8635, 547-557, viii-ix [13 p.]Article

Update on rituximabEISENBERG, R.Annals of the rheumatic diseases. 2005, Vol 64, pp iv55-iv57, issn 0003-4967, SUP4Conference Paper

Chronic neuropathy with igm antiganglioside antibodies: Lack of long term response to rituximabROJAS-GARCIA, R; GALLARDO, E; DE ANDRES, I et al.Neurology. 2003, Vol 61, Num 12, pp 1814-1816, issn 0028-3878, 3 p.Article

Rituximab-Induced Hypersensitivity PneumonitisTONELLI, Adriano R; LOTTENBERG, Richard; ALLAN, Robert W et al.Respiration (Basel). 2009, Vol 78, Num 2, pp 225-229, issn 0025-7931, 5 p.Article

Rituximab in Lymphocyte-Predominant Hodgkin DiseaseAZIM, Hatem A; PRUNERI, Giancarlo; COCOROCCHIO, Emilia et al.Oncology. 2009, Vol 76, Num 1, pp 26-29, issn 0030-2414, 4 p.Article

Rituximab treatment of the anti-synthetase syndrome―a retrospective case seriesSEM, Marthe; MOLBERG, Øyvind; LUND, May Brit et al.Rheumatology (Oxford. Print). 2009, Vol 48, Num 8, pp 968-971, issn 1462-0324, 4 p.Article

Anticorps monoclonal anti-CD20 et traitement des maladies auto-immunes = Rituximab and auto-immune disorders therapyQUINT, L.La Revue de médecine interne (Paris). 2004, Vol 25, Num 10, pp 752-754, issn 0248-8663, 3 p.Article

Quantitative analysis of protein co-localization on B cells opsonized with rituximab and complement using the ImageStream multispectral imaging flow cytometerBEUM, Paul V; LINDORFER, Margaret A; HALL, Brian E et al.Journal of immunological methods. 2006, Vol 317, Num 1-2, pp 90-99, issn 0022-1759, 10 p.Article

The therapeutic potential of anti-CD20 What do B-cells do?EISENBERG, Robert; LOONEY, R. John.Clinical immunology (Orlando, Fla. Print). 2005, Vol 117, Num 3, pp 207-213, issn 1521-6616, 7 p.Article

Rituximab therapy for chronic periaortitisMARITATI, Federica; CORRADI, Domenico; VERSARI, Annibale et al.Annals of the rheumatic diseases. 2012, Vol 71, Num 7, pp 1262-1264, issn 0003-4967, 3 p.Article

Rituximab and its Use in Autoimmune Bulbous DisordersDANIEL, Benjamin S; MURRELL, Dédée F; JOLY, Pascal et al.Dermatologic clinics. 2011, Vol 29, Num 4, issn 0733-8635, viii, 571-575 [6 p.]Article

Excessively increased CSF tau in progressive multifocal leulcoencephalopathyBRÜGGEMANN, Norbert; GOTTSCHALK, Stefan; KÖRTKE, Detlev et al.Clinical neurology and neurosurgery (Dutch-Flemish ed.). 2012, Vol 114, Num 6, pp 762-764, issn 0303-8467, 3 p.Article

Target-induced natural killer cell loss as a measure of NK cell responsesWARREN, Hilary S.Journal of immunological methods. 2011, Vol 370, Num 1-2, pp 86-92, issn 0022-1759, 7 p.Article

Complement activation and C3b deposition on rituximab-opsonized cells substantially blocks binding of phycoerythrin-labeled anti-mouse IgG probes to rituximabBEUM, Paul V; KENNEDY, Adam D; YONGLI LI et al.Journal of immunological methods. 2004, Vol 294, Num 1-2, pp 37-42, issn 0022-1759, 6 p.Article

  • Page / 102